Skip to main content

Table 4 The effects of 8 weeks’ soy isoflavones on quality of life and mental status of migraine patients

From: Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial

Variable

Soy isoflavones (n = 44)

Placebo (n = 44)

P b

P c

Before

After

Change

P a

Before

After

Change

P a

Quality of life

(MSQ score)

54.49 ± 13.28

71.25 ± 10.15

16.76 ± 10.15

 < 0.001

50.95 ± 21.46

53.48 ± 21.68

2.52 ± 13

0.205

 < 0.001

 < 0.001

Mental status

Depression

14.72 ± 9.17

14.75 ± 9.19

0.02 ± 1.63

0.927

17.31 ± 10.80

17.06 ± 10.42

-0.25 ± 2.78

0.555

0.272

0.978

Anxiety

14.65 ± 6.97

14.56 ± 7.07

-0.09 ± 1.81

0.741

16.75 ± 9.55

16.50 ± 9.23

-0.25 ± 1.84

0.374

0.274

0.922

Stress

18.75 ± 7.61

18.11 ± 8.35

-0.63 ± 3.43

0.225

24.29 ± 10.29

23.65 ± 10.12

-0.63 ± 3.67

0.258

0.006

0.957

  1. Variables expressed as mean ± SD
  2. a Paired t-test was used to compare pre-post tests
  3. b Independent sample t-test was used to compare groups two by two
  4. c Obtained from analysis of covariance in the adjusted models (adjusted for baseline value and certain dietary factors such as vitamin D, thiamin, riboflavin, niacin, cobalamin and magnesium)